Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Either 50:1 or 70:1
THANKS.
Is there a ratio of what each post-split share will get of the new company, if not a 1:1 ?
Appreciate your help / thoughts.
Been discussion from 4 all the way to 50.
Personally 10 would be good.
Do you have any idea on the r/s ratio? I have looked around but could not find it so readily.
Thanks
Only cure needed is Cully's exit. This will fly not because of merger but investors knowing Cully is out.
Just like after WW II and the exit of Hitler.
a huge upgrade:listed on NASDAQ!
"As home to many innovative and growth-oriented life science companies, Nasdaq is a natural fit for Savara," said Rob Neville, CEO of Savara. "We believe the move to Nasdaq will provide strong visibility for our stock, good trading liquidity in our shares, and provide the company with greater exposure to institutional investors."
http://masttherapeutics.com/investors/news/?releaseid=2260932
The reverse split is a cure for this stock. Culley diluted it for years until it reached a shameful amount of outstanding shares. Moreover the merger needs another redistribution among the shareholders then the R/S is inevitable as well as it is required by the NYSEMKT rules for the merger, but, for these same reasons,it shouldn't be unfavourable to Mast long.
A smaller float coupled with the lock-up period for old Savara investors and a renovated management can be finally the rebirth of the company.
IMO a market capitalization around $500M after the merger and after some positive news about trials isn't unrealistic
That's a understatement .... "I have gotten the impression from almost all Mast holders that McCully is someone they'd prefer never to see or hear from again."
In seven years, A RS, 6 offerings, share count quadrupling, 5 new drugs, 5 failed tests and and $100 dollars invested going to about a dime. Top it off his salary goes from $75000 a year to $250,000 with bonuses. Yes can not wait till the door hits him on the way out. Has to be the worst CEO in any BIO field.
Agreed that Rob Neville is absolutely a class act. While Savara was privately held and before engaging in merger talks with Mast, I could always count on a straight answer from Rob if I emailed or called him with a question. Now, he has to be extremely circumspect with material non-public information. He is still quite responsive.
I have gotten the impression from almost all Mast holders that McCully is someone they'd prefer never to see or hear from again.
Yes, I have emailed and called investor relations and they shared only present shareholders of Savara are privy to that info and no other info can be discussed.
Also shared there are sites but no info up to date. Just going by old info.
Only reason holding now is Savara CEO. By his education and business background he seems like a class act. Plus he seems to have shareholders and company at best interest unlike Cully who was in this for himself all along. Could really care less about shareholders which is present concern. Would not put it past him to ?xv!xx shareholders one final time.
Pray, Those are very old numbers for Savara. I have been a Savara shareholder since Series B in 2012 and I believe we've passed Series C as well. I just exercised my Series B warrants to buy more Savara shares at $3.13 in advance of the pending merger. This against a value at our last funding round of over $5/sh.
The pitchbook information also was back when Savara had 19 holders. I believe we are now much more broadly held: in the several hundreds. The Savara story (forgetting about MAST at the moment) has resonated well with investors.
Also holding a number of MSTX shares.
https://pitchbook.com/profiles/savara-pharmaceuticals-profile-investors-funding-valuation-and-analysis
Then look at
“Savara Pharmaceuticals Cap Table”
Under Series A 1,799,906 present shares @ $1.81 also notice this is only 11.45% of value.
If 11% is $1.81 I am assuming the other 79% would at least double the value hence $4.00.
Also note they have 11-50 full time employees were Mast only has 6 presently, and basically McCully gets paid as if he is an additional 6 ($300,000 yearly).
Hope this helps ....
Could you point me to those estimates, I've been looking and can't find them honestly
Thanks a bunch!! Pray
I have seen estimates of about $4.00 per share. If that's the case the RS will be around 1/25.
The more I read on Savarapharma the more I like it,is anybody aware of the company's value per share?
Thanks for your response Pray
GL t you too, hope to see more buying soon
Understood and i respect that Masala. But TA is a helpfully tool showing these positive and negative sways.. Volume was very strong today. If this can continue this will be great! GL
Mstx is trading is based on a binary events, charts aren't helpful gotta throw them out.
.15 hit AH. lets c what pre market brings. GLTA
i disagree. .15 has been resistance. so there is truth to his chart. if that falls that .17 imo is next for resistance but lets take out .16 first. Clay knows what hes doin..
Nothing in the chart work really, just smart marketing
* * $MSTX Video Chart 04-03-17 * *
Link to Video - click here to watch the technical chart video
still a lot of uncertainty regarding the merger. closing in on vote now
Any possibility about antimicrobial AIR001 Phase 1/2 preliminary results from UP?
nice moves.. level II shows lots of burst and basket buying.. institutions getting in on merger news at these rates.. GLTA
If it breaks .1475 will go a lot higher.
... Hit .1470 then dropped back ....
What are your opinions on selling some shares for +50% gain or continue to hold long term? Appreciate your thoughts and time.
.1428 pretty sure it can get over .15 lol
The lock up period after the merger should raise strongly the PPS. Savara current stakeholders and Mast managers can't sell the new shares for several months, I think that the amount of shares locked are about the 70-80% of the float.Very few shares could be traded after the merger and if all the good news about AIR, Savara drugs and Epic database will come out after the merger easily a x2 or x3 or much more.
IMO
Volume over 5 million in trades in less than an hour .... usually between 2-4 million daily.
I can't believe the crowd hasn't found this gem yet.
My average is .41, not going anywhere here Hahahaha
congrats. no profit unless you sell. resistances are meant to be broken. official merger news still to come. DMA50 to becoming support imo. GLTA
I'm out, sorry guys, that's the hard law of trading. Overbought in TU 4H and also daily STO is near 90, so I will wait for a re-entry point maybe 0.10$
That's my sole and only my decision. Do your own DD before any trade!
GLTA
MA50 should become support, then testing MA200 @0.22$
GL, still in with 180,000 shares
yup.. pre/ah will move this
8K is an unofficial announcement that the merger has officially been approved. WOOOHOOO! IMO.
TShaq
Yup, he better cover real soon! Nice try shorty
My advice would be to COVER very soon shortie.
Reverse split on the way.. only way it can get over 15 cents what a shame
This security is ready to go back to .50PS pre merger and 2.00PS post merger.
What is the value they gave the pps for merger?
TA looking better. .12 needs to breakout and become support already..
Now we test the 50 MA, or is it to bust people who had placed a stop? But, NICE SHOT!
Looks like at shooting star if you ask me
I'm not able to post a chart with this app. I'm on StockTwits with charts. Price action finally bounced of .10, with a multi-month uptrend, wedge from .24, daily green candle breaking out of triangle, oversold. Plus merging with Savara. I'm in with 57k shares. Just suggesting others look at this trade setup.
I don't see this. Maybe you could post a chart. No wedge. I think your just baseless pumping.
Followers
|
304
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
15766
|
Created
|
08/30/05
|
Type
|
Free
|
Moderators |
We are a publicly traded biopharmaceutical company headquartered in San Diego, California.
We are leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop vepoloxamer, our lead product candidate, for serious or life-threatening diseases with significant unmet needs.
To learn more about our company, please see our Letter from the CEO.
http://www.masttherapeutics.com/investors/
Purpose
Condition | Intervention | Phase |
---|---|---|
Vaso-occlusive Crisis Sickle Cell Disease | Drug: Saline Drug: MST-188 | Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
Official Title: | Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis |
Estimated Enrollment: | 388 |
Study Start Date: | May 2013 |
Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: MST-188 MST-188 injection administered as a continuous infusion 100 mg/kg for 1 hour followed by 30 mg/kg/hr for up to 48 hours. | Drug: MST-188 Other Name: vepoloxamer |
Placebo Comparator: Saline Saline administered as a continuous infusion for up to 49 hours | Drug: Saline |
Ages Eligible for Study: | 4 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Mast Therapeutics CT.gov Call Center | 1-888-965-1238 |
Study Director: | Edwin L. Parsley, D.O. | Mast Therapeutics, Inc. |
Responsible Party: | Mast Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT01737814 History of Changes |
Other Study ID Numbers: | MST-188-01 |
Study First Received: | November 27, 2012 |
Last Updated: | September 24, 2015 |
Health Authority: | United States: Food and Drug Administration Belgium: Federal Agency for Medicines and Health Products, FAMHP Brazil: National Committee of Ethics in Research Dominican Republic: Consejo Nacional de Bioetica en Salud Jordan: Jordanian Food and Drug Administration Lebanon: Institutional Review Board Oman: Academic Accreditation Authority Panama: Ministry of Health Spain: Ministerio de Sanidad, Servicios Sociales e Igualdad Saudi Arabia: Saudi Food and Drug Administration Turkey: Drug and Medical Device Institution Jamaica: Ministry of Health |
sickle cell disease vaso-occlusive crisis |
Anemia, Sickle Cell Anemia Anemia, Hemolytic Anemia, Hemolytic, Congenital | Genetic Diseases, Inborn Hematologic Diseases Hemoglobinopathies |
MST-188 (purified poloxamer 188) is an investigational agent that has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. We initially are developing MST-188 as a treatment for complications arising from sickle cell disease.
AIR001 is a sodium nitrite solution for intermittent inhalation via nebulizer. Nitrite is a direct vasodilator and can be recycled in vivo to form nitric oxide (NO) independent of the classical NO synthase (NOS) pathway. Nitrite mediated NO formation has several beneficial effects, including dilation of blood vessels and reduction of inflammation and undesirable cell growth. Generation of NO from sodium nitrite is not dependent upon endothelial function and is enhanced in the setting of tissue hypoxia and acidosis, conditions in which NOS activity typically is depressed. In early clinical studies, AIR001 demonstrated positive hemodynamic effects with reductions observed in right atrial pressure and pulmonary capillary wedge pressure, as well as improvements in mean pulmonary artery pressures and cardiac output.
We are developing AIR001 for treatment of heart failure with preserved ejection fraction (HFpEF), a condition that affects millions in the U.S. and for which no proven therapeutic agent is available. Numerous lines of evidence suggest that HFpEF is a disease of NO deficiency. We are supporting two institution-sponsored Phase 2a studies in patients with HFpEF to evaluate acute hemodynamic effects of AIR001 and to evaluate its acute effects versus placebo on submaximal oxygen consumption and exercise hemodynamics.
AIR001 Inhalation Solution is sodium nitrite formulated with a phosphate buffer into an inhalation solution. Nitrite is a physiological signaling molecule with roles in intravascular endocrine nitric oxide (NO) production, hypoxic vasodilation, signaling, and cytoprotection after ischemia-reperfusion. Nitrite serves as the largest physiologic reservoir of NO and can be converted to NO independent of NO synthase (NOS) activity.
In experimental models, nitrite use demonstrated improved remodeling both in the pulmonary vasculature and right ventricle. Hemodynamic effects include venodilation with reductions in right atrial pressures, pulmonary and systemic vasodilation with reductions in pulmonary vascular resistance and left atrial pressures, and improved cardiac relaxation. In addition, recent clinical and nonclinical studies have demonstrated that nitrite can stimulate mitochondrial biogenesis and mitochondrial fusion and decrease mitochondrial oxygen consumption through a mechanism distinct from that of NO, which may have utility in treating heart failure.
We obtained the AIR001 program through our acquisition of Aires Pharmaceuticals, Inc. in February 2014. Prior to the acquisition, AIR001 had been tested in more than 120 healthy volunteers and patients with various forms of pulmonary hypertension in three Phase 1 studies and in one Phase 2 study in patients with pulmonary arterial hypertension. While the Phase 2 study was prematurely terminated due to Aires’ capital constraints prior to the acquisition, preliminary data from the study are positive, showing improvements in hemodynamic parameters and in exercise capacity from baseline. There were no treatment-related serious adverse events and methemoglobin levels remained normal (< 1.5%), which distinguishes AIR001 from safety concerns associated with intravenously-administered nitrite.
Data from these early clinical studies support continued clinical development of AIR001. Given the observed hemodynamic improvements of decreased right arterial pressure, decreased pulmonary capillary wedge (or left atrial pressure), as well as improvements in pulmonary vascular resistance and cardiac lusitropic effects, AIR001 may benefit patients with exercise impairment due to heart failure with preserved ejection fraction (HFpEF), for whom these are all desirable effects.
Hemodynamic improvements, improvements in pulmonary artery pressures, and cardiac lusitropic effects observed in earlier studies of AIR001 support AIR001’s potential to benefit patients with heart failure with preserved ejection fraction (HFpEF). We currently are pursuing clinical development of AIR001 for that patient population.
Event Timing
Initiate tQT/QTc Study Completed
Secure Orphan Designation for MST-188 for SCD in EU Completed
Activate First Site in Phase 3 Study Completed
File New Patent Applications Completed
Dose First Subject in Phase 3 Study Completed
Report data from tQT/QTc Study Q3 Completed and Primary Endpoints Met
Request Orphan Designation for MST-188 for ALI in U.S. Q3 Completed and Designation Granted By FDA
Initiate Nonclinical Proof-of-Concept Study in Heart Failure Q3 Completed and POC Data to be released Q1 '14
2014 Activities
Event Timing
Present Data From Nonclinical Proof-of-Concept Study In Heart Failure Q1 '14 Data Released 01/06/14'Showed Significant Statistical Improvement"
Initiate Phase 2 Study in ALI Q1 '14 Initiated
Outcome of review of application for Unique Name Designation For Purified Poloxamer 188 From U.S. Adopted Names Counsel Q1 '14 Granted and Named VEPOLOXAMER
Open First Ex-U.S. Clinical Sites in Phase 3 Trial Q1 '14. Initiated and On Schedule
Submit Abstract with Heart Failure Study Biomarker Data to Major Medical Conference Q2 '14
Request Orphan Designation for ALI in EU Q2 '14 Application Submitted
Initiate Nonclinical POC Study in Stroke Q2 '14 Study Initiated
Initiate EPIC Sub-Study Q2 '14 Initiated On Schedule 06/14/14
Report Results from Phase 2 Study of AIR001 in PAH Q3 '14 Positive Top line Data released 9/8/14
Initiate study with Dept of Defense: MST-188 Resuscitation from major trauma '14 CRADA with US Military Initiated Q3 '14
Receive protocol from FDA for Phase 2 Heart Failure Study Q4'14 FDA Approves Heart Failure Study 12/9/14
2015 Event Schedule
Initiate dosing Phase2a study in AIR001 Q1 '15. INITIATED 2/4/15
Nonclinical Study EMBOLIC STROKE Data Q1 '15: POSITIVE DATA RELEASED 2/11/15
Report nonclinical data for repeat dose on Vepoloxamer in Heart Failure Q1 '15 POSITIVE DATA RELEASE 03/02/15
Phase 2 Study HEART FAILURE Initiate Enrollment Q2 '15 INITIATED 3/23/15
EPIC EXTENSION STUDY (Repeat Exposure) Initiate Enrollment 1st Half '15 INITIATED 5/26/15
Phase 2a Study of AIR001 (WHO GROUP 2) in HFpEF Preliminary Data 2nd Half '15
Phase 2 Study Heart Failure Interim Safety Analysis 2nd Half '15
EPIC STUDY COMPLETE ENROLLMENT Q4 '15
2016 EVENTS
EPIC Top Line Data Q1 2016
Video of Management of Mast Therapeutics $MSTX speaking about MST-188 for Sickle Cell Disease ,orphan drug
http://www.youtube.com/watch?v=eI7inPOiyZM&feature=youtu.be
http://www.masttherapeutics.com/wp-content/uploads/2013/04/EPIC-An-Ongoing-Pivotal-Phase-3-Study-in-Patients-with-Sickle-Cell-Disease-Aug-21-2013.
Filing Company | Date of Filing | Total Reported Shares Owned | Shares Reported on 13F | |
---|---|---|---|---|
Baker Bros LLC | 12/31/14 | 4,774,434 | 4,774,434 | |
BVF Inc. | 3/31/15 | 7,241,600 | 7,241,600! | |
SC 13G | FRANKLIN RESOURCES INC | 02/04/15 | 11,946,100 | 11,946,100 |
Reported via | Event Date | Name | Ticker | Shares * | Change | % of Portfolio |
---|---|---|---|---|---|---|
13F MPM Asset Management | MSTX | 2,551,851 | ||||
13F Vanguard Group | MSTX | 3,382,483 |
http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=2&g=0&id=p32395513381
http://stockcharts.com/h-sc/ui?s=MSTX&p=D&b=9&g=0&id=p36778398928
http://stockcharts.com/freecharts/gallery.html?MSTX
P: 858-552-0866 F: 858-552-0876
General Inquiries
info@mastthera.com
Investor Relations Contact
ir@mastthera.com
Business Development Contact
busdev@mastthera.com
Careers Contact
hr@mastthera.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |